ACLX – Arcellx Inc
ACLX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.97
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.05
EPS Last/This Y
EPS This/Next Y
2.74
Price
115.07
Target Price
115
Analyst Recom
3
Performance Q
71.9
Upside
N/A
Beta
0.18
Ticker: ACLX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | ACLX | 115.04 | 0.58 | 0.22 | 27951 |
| 2026-04-24 | ACLX | 115.02 | 0.58 | 1.18 | 28099 |
| 2026-04-27 | ACLX | 115.07 | 0.69 | 0.43 | 30291 |
| 2026-04-28 | ACLX | 115.07 | 0.69 | 0.53 | 30291 |
| 2026-04-29 | ACLX | 115.07 | 0.69 | 0.53 | 30291 |
| 2026-04-30 | ACLX | 115.07 | 0.69 | 0.53 | 30291 |
| 2026-05-01 | ACLX | 115.07 | 0.69 | 0.53 | 30291 |
| 2026-05-04 | ACLX | 115.07 | 0.69 | 0.53 | 30291 |
| 2026-05-05 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-06 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-07 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-08 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-11 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-12 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-13 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-14 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-15 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-18 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-19 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-20 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-21 | ACLX | 115.07 | N/A | N/A | 0 |
| 2026-05-22 | ACLX | 115.07 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | ACLX | 115.04 | 9.8 | -93.5 | -4.20 |
| 2026-04-24 | ACLX | 115.03 | 9.8 | -93.4 | -4.20 |
| 2026-04-27 | ACLX | 115.07 | 9.8 | -93.5 | -4.20 |
| 2026-04-28 | ACLX | 115.07 | 9.8 | -93.4 | -4.20 |
| 2026-04-29 | ACLX | 115.07 | 9.8 | -93.4 | -4.20 |
| 2026-04-30 | ACLX | 115.07 | 9.8 | -93.4 | -4.20 |
| 2026-05-01 | ACLX | 115.07 | 9.8 | -93.4 | -4.22 |
| 2026-05-04 | ACLX | 115.07 | 9.8 | -93.4 | -4.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | ACLX | -1.11 | -16.20 | 5.00 |
| 2026-04-24 | ACLX | -1.11 | -16.20 | 5.00 |
| 2026-04-27 | ACLX | -1.11 | -16.07 | 3.97 |
| 2026-04-28 | ACLX | -1.10 | -16.07 | 3.97 |
| 2026-04-29 | ACLX | -1.10 | -16.07 | 3.97 |
| 2026-04-30 | ACLX | -1.10 | -16.07 | 3.97 |
| 2026-05-01 | ACLX | -1.10 | -16.07 | 3.97 |
| 2026-05-04 | ACLX | -1.10 | 0 | 3.97 |
| 2026-05-05 | ACLX | -1.10 | 0 | 3.97 |
| 2026-05-06 | ACLX | -1.10 | 0 | 3.97 |
| 2026-05-07 | ACLX | -1.10 | 0 | 3.97 |
| 2026-05-08 | ACLX | -1.10 | 0 | 3.97 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.01
Avg. EPS Est. Current Quarter
-1.02
Avg. EPS Est. Next Quarter
-1.06
Insider Transactions
-1.1
Institutional Transactions
Beta
0.18
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
7
Fair Value
Quality Score
16
Growth Score
38
Sentiment Score
84
Actual DrawDown %
Max Drawdown 5-Year %
Target Price
115
P/E
Forward P/E
PEG
P/S
302.05
P/B
16.57
P/Free Cash Flow
EPS
-4.05
Average EPS Est. Cur. Y
-4.22
EPS Next Y. (Est.)
-1.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1027.25
Relative Volume
Return on Equity vs Sector %
-84.2
Return on Equity vs Industry %
-67.4
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-93.4
No data found for ACLX
Arcellx, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 209
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.
ACLX
Latest News
—
Caricamento notizie per ACLX…
stock quote shares ACLX – Arcellx Inc Stock Price stock today
news today ACLX – Arcellx Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACLX – Arcellx Inc yahoo finance google finance
stock history ACLX – Arcellx Inc invest stock market
stock prices ACLX premarket after hours
ticker ACLX fair value insiders trading